TYRA Stock: Price, Earnings History and SEC Filings
Tyra Biosciences, Inc. (TYRA) last traded at $21.07, down 1.91% on the latest session and down 3.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.69 against an analyst estimate of $-0.67, a miss of 3.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TYRA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.69 | $-0.67 | -2.99% |
| Mar 2026 | May 13, 2026 | $-0.64 | $-0.60 | -6.67% |
| Dec 2025 | Mar 2, 2026 | $-0.57 | $-0.54 | -5.56% |
| Sep 2025 | Nov 5, 2025 | $-0.50 | $-0.50 | +0.00% |
TYRA beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How TYRA reacts to earnings
Across its last 8 earnings releases, TYRA moved 4.7% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | -20.97% |
| 2026-05-13 | Before open | +3.79% |
| 2026-03-02 | After close | +1.51% |
| 2025-11-05 | After close | -3.64% |
| 2025-08-14 | After close | +0.28% |
| 2025-05-08 | After close | +0.20% |
| 2025-03-27 | After close | +1.14% |
| 2024-11-07 | After close | -6.06% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TYRA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$120M | -$95M | – | $-2.01 |
| 2024 | – | -$86M | -$70M | – | $-1.51 |
| 2023 | – | -$69M | -$51M | – | $-1.62 |
| 2022 | – | -$55M | -$51M | – | $-1.32 |
| 2021 | – | -$26M | -$24M | – | $-1.91 |
| 2020 | – | -$9M | -$8M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TYRA
- 8-K · Sep 15, 2026Other events, Financial statements and exhibits
- 424B5 · Sep 15, 2026
- 8-K · Sep 9, 2026Other events
- 424B5 · Aug 4, 2026
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 2, 2026Shareholder vote
- 10-Q · May 13, 2026
- 8-K · May 13, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 17, 2026
Insider filing activity
TYRA insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TYRA news
- Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book ValueOct 31, 2026 · finance.yahoo.com
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc. (TYRA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.